A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.

被引：15
|
作者：
Gabrail, Nashat Y.
Hamilton, Erika P.
Elias, Anthony D.
Rimawi, Mothaffar F.
Li, Chao
Corvez, Maria Margarita
Li, Wei
Feng, Ying
Wei, Jiao
Greene, Stephanie
Patterson, John
Zeng, Qingping
Hui, Ai-Min
机构：
[1] Gabrail Canc Ctr Res LLC, Canton, OH USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Tennessee Oncol PLLC, Nashville, TN USA
[4] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA
[5] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA
[6] Shanghai Fosun Pharmaceut Dev Co Ltd, Shanghai, Peoples R China
[7] Orinove Inc, Newbury, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3080
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
    Tsimberidou, Apostolia M.
    Vining, David J.
    Arora, Sukeshi P.
    de Achaval, Sofia
    Larson, Jeffrey
    Kauh, John
    Cartwright, Carrie
    Avritscher, Rony
    Alibhai, Imran
    Tweardy, David J.
    Kaseb, Ahmed O.
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 965 - 974
  • [22] Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors
    Tsimberidou, Apostolia Maria
    Vining, David J.
    Arora, Sukeshi Patel
    de Achaval, Sofia
    Larson, Jeffrey
    Cartwright, Carrie
    Avritscher, Rony
    Alibhai, Imran
    Kaseb, Ahmed Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)
    Shapiro, Geoffrey
    Wesolowski, Robert
    Middleton, Mark
    Devoe, Craig
    Constantinidou, Anastasia
    Papadatos-Pastos, Dionysis
    Fricano, Marjorie
    Zhang, Yanqiong
    Karan, Sharon
    Pollard, John
    Penney, Marina
    Asmal, Mohammed
    Renshaw, F. Gary
    Fields, Scott Z.
    Yap, Timothy A.
    CANCER RESEARCH, 2016, 76
  • [24] Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1/Nek2 inhibitor, in patients with advanced refractory solid tumors
    Su, Wu-Chou
    Bai, Li-Yuan
    Hsiao, Hui-Hua
    Shiah, Her-Shyong
    Yeh, Yu-Min
    Chen, Shang-Hung
    Wu, Shang-Yin
    Wang, Hui-Ching
    Tsai, Hui-Jen
    Chang, Kwang-Yu
    Tsai, Jui-Hung
    Lee, Chun-Hui
    Lee, Chieh Hua
    Chao, Yu-Sheng
    Chen, Li-Tzong
    CANCER RESEARCH, 2024, 84 (07)
  • [25] A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors
    Ratain, M. J.
    Benedetti, F. M.
    Janisch, L.
    Khor, S.
    Schilsky, R. L.
    Cohen, E. E.
    Maitland, M. L.
    Elias, L.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors.
    Doi, T.
    Murakami, H.
    Wan, K.
    Miki, M.
    Kotani, H.
    Sakamoto, N.
    Yamamoto, N.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] A phase 1 trial of motexafin gadolinium and docetaxel for advanced solid tumors.
    Ramnath, N
    Chatta, G
    Egorin, M
    Phan, S
    Creaven, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 237S - 237S
  • [28] ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors
    Ghazaly, Essam Ahmed
    Rizzuto, Ivana
    Gabra, Hani
    Habib, Nagy A.
    Leonard, Robert C. F.
    Wasan, Harpreet
    McGuigan, Christopher
    Blagden, Sarah Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors
    Cassier, P.
    Eberst, L.
    Garin, G.
    Courbebaisse, Y.
    Terret, C.
    Robert, M.
    Frenel, J. -S.
    Depil, S.
    Delord, J. -P.
    Perol, D.
    Ray-Coquard, I. L.
    Bidaux, A. -S.
    Tabone-Eglinger, S.
    Gilles-Afchain, L.
    Treilleux, I.
    Wang, Q.
    Ducarouge, B.
    Mehlen, P.
    Blay, J. -Y.
    Gomez-Roca, C. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
    Champiat, Stephane
    Cassier, Philippe A.
    Kotecki, Nuria
    Korakis, Iphigenie
    Vinceneux, Armelle
    Jungels, Christiane
    Blatchford, Jon
    Elgadi, Mabrouk M.
    Clarke, Nicole
    Fromond, Claudia
    Poirier, Nicolas
    Vasseur, Berangere
    Marabelle, Aurelien
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345